Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs
Ahmed Kamal , Menha Swellam , Nevin M. Shalaby , Marwa K. Darwish , Eslam M. El-Nahrery
Journal of Translational Genetics and Genomics ›› 2024, Vol. 8 ›› Issue (2) : 162 -85.
Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs
Long non-coding RNAs (lncRNAs) are a class of RNA transcripts that are long (i.e., more than 200 nucleotides) and not translated into proteins. They have recently emerged as potential treatment targets for numerous disorders due to their involvement in multiple cellular functions such as gene regulation, epigenetic modulation, and chromatin organization. This review highlights the current state of lncRNA-based therapeutics, the potential of lncRNAs as drug targets for treating human diseases, the various strategies and types of RNA-based therapeutics, and the complications of developing lncRNA-based drugs. We conclude that lncRNA-based therapeutics represent a promising class of drugs that can potentially treat various human diseases and that further research is needed to fully realize their therapeutic potential.
Long non-coding RNA / RNA-based therapeutics / LncRNA-based drugs / small interfering RNAs / short hairpin RNAs / microRNAs
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Duran R, Wei H, Kim DH, Wu JQ. Invited review: long non-coding RNAs: important regulators in the development, function and disorders of the central nervous system.Neuropathol Appl Neurobiol2019;45:538-56 PMCID:PMC6626588 |
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age.EMBO Mol Med2014;6:851-64 PMCID:PMC4119351 |
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis.Ocul Immunol Inflamm1999;7:189-98 |
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
Regulus Therapeutics I. RG-125 (AZD4076), a microRNA therapeutic targeting microRNA-103/107 for the treatment of NASH in patients with type 2 diabetes/pre-diabetes, selected as clinical candidate by AstraZeneca. 2015. Available from: https://www.prnewswire.com/news-releases/rg-125-azd4076-a-microrna-therapeutic-targeting-microrna-103107-for-the-treatment-of-nash-in-patients-with-type-2-diabetespre-diabetes-selected-as-clinical-candidate-by-astrazeneca-300062261.html [Last accessed on 1 Apr 2024] |
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
da Silva AMG, Cruz MS, de Souza KSC, Silbiger VN. Long non-coding RNA and circular RNA: new perspectives for molecular pathophysiology of atrial fibrillation.Mol Biol Rep2023;50:2835-45 |
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
/
| 〈 |
|
〉 |